Skip Navigation

JNCI Journal of the National Cancer Institute 2006 98(2):86-87; doi:10.1093/jnci/djj043
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tuma, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tuma, R. S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2006.

NEWS

Latest Studies Hint at Survival Advantage With Aromatase Inhibitors in Early Breast Cancer

Rabiya S. Tuma

The first 10% of the full text of this article appears below.

Adjuvant therapy with aromatase inhibitors following tamoxifen improves disease-free survival in women with early-stage, hormone-responsive breast cancer. A meta-analysis presented at the San Antonio Breast Cancer Symposium in December suggests that anastrozole (Arimidex) also improves overall survival in these patients. Moreover, new data show that adjuvant therapy with letrozole (Femara) improves disease-free survival and shows a trend toward improved overall survival even after a substantial gap between completion of tamoxifen and start of letrozole therapy.

Interim results from several trials showed improved event-free survival and a trend for improved overall survival in women who switched to aromatase inhibitor therapy after 2–3 years on tamoxifen compared with those who . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?